TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03685890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: One infusion of nivolumab (Opdivo®) 480mg (flat dose) in NaCl (Natriumklorid Baxter Viaflo, 9 mg/ml) during 60 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isolated limb perfusion (ILP)
Description: Patients will be treated with ILP according to clinical routine at each separate site. The procedure is performed under general anaesthesia. The major artery and vein of the limb is catheterized, and a tourniquet is placed proximally on the limb. Continuous leakage monitoring is performed. The perfusate is heated to 40C and after ensuring steady state, melphalan (Alkeran®) at a dose of 13 mg/L (upper limb) or 10 mg/L (lower limb) is infused into the circulation during 20 minutes for a total perfusion time of 60 minutes. According to local routine tasonermin (Beromun®) will be added to the perfusate 30 minutes before the melphalan as a bolus dose of 1-4 mg.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Isolated limb perfusion (ILP)
Description: Patients will be treated with ILP according to clinical routine at each separate site. The procedure is performed under general anaesthesia. The major artery and vein of the limb is catheterized, and a tourniquet is placed proximally on the limb. Continuous leakage monitoring is performed. The perfusate is heated to 40C and after ensuring steady state, melphalan (Alkeran®) at a dose of 13 mg/L (upper limb) or 10 mg/L (lower limb) is infused into the circulation during 20 minutes for a total perfusion time of 60 minutes. According to local routine tasonermin (Beromun®) will be added to the perfusate 30 minutes before the melphalan as a bolus dose of 1-4 mg.
Study: NCT03077087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thin Integra® (125 cm2)
Description: 125 cm2 represents approximately 0.7% of an average sized patient's total body surface area. The remaining injury areas would be covered with standard-thickness Integra® only. The donor graft, a 4 cm x 10 cm sheet of skin, would be meshed in a 3:1 ratio to be expanded to cover the 125 cm2 sheet of thin Integra®. The patient's post-operative care would be largely unchanged, although the patient would have a donor site of 40 cm2 that would be dressed and managed in the usual fashion.
Study: NCT04620798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate vs. delayed provision of antibody test results
Description: The primary experiment will be assessing whether provision of the antibody test results leads to behavior change with respect to personal protective behaviors. To that end, we will randomize all participants to a trial arm that immediately receive results (within 24 hours) or a trial arm with a delayed provision of results (after 4 weeks).
Study: NCT03545971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: IBI310 is anti CTLA-4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: IBI310 is anti CTLA-4 antibody
Study: NCT04439539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Tenofovir alafenamide film-coated tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 will be administered orally.
Study: NCT00874237

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled loxapine
Description: Inhaled Staccato Loxapine 10 mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled loxapine
Description: Inhaled Staccato Loxapine 10 mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled loxapine
Description: Inhaled Staccato Loxapine 10 mg single dose
Study: NCT00638937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given PO
Study: NCT02586714

Intervention type: OTHER
Intervention: No intervention
Description: Observation only

Intervention type: OTHER
Intervention: No intervention
Description: Observation only

Intervention type: OTHER
Intervention: No intervention
Description: Observation only
Study: NCT00874237

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled loxapine
Description: Inhaled Staccato Loxapine 10 mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled loxapine
Description: Inhaled Staccato Loxapine 10 mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled loxapine
Description: Inhaled Staccato Loxapine 10 mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo
Description: Inhaled Staccato placebo single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo
Description: Inhaled Staccato placebo single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo
Description: Inhaled Staccato placebo single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo
Description: Inhaled Staccato placebo single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo
Description: Inhaled Staccato placebo single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo
Description: Inhaled Staccato placebo single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Oral moxifloxacin
Description: Oral moxifloxacin 400 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Oral moxifloxacin
Description: Oral moxifloxacin 400 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Oral moxifloxacin
Description: Oral moxifloxacin 400 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Oral moxifloxacin
Description: Oral moxifloxacin 400 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Oral moxifloxacin
Description: Oral moxifloxacin 400 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Oral moxifloxacin
Description: Oral moxifloxacin 400 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo
Description: Oral placebo similar in appearance to moxifloxacin 400 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo
Description: Oral placebo similar in appearance to moxifloxacin 400 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo
Description: Oral placebo similar in appearance to moxifloxacin 400 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo
Description: Oral placebo similar in appearance to moxifloxacin 400 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo
Description: Oral placebo similar in appearance to moxifloxacin 400 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo
Description: Oral placebo similar in appearance to moxifloxacin 400 mg
Study: NCT04003090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: After treatment with a solution containing citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride patients underwent a 23G standard 3-port pars plana vitrectomy. The vitreous sample was taken at the beginning of the surgery and then analyzed.
Study: NCT03991026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy food and Education/Cooking Classes
Description: The intervention includes providing weekly seasonal produce and healthy foods to participants in addition to an education/cooking class that will be tailored to Diabetes Mellitus, Type II.
Study: NCT03545971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: IBI310 is anti CTLA-4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: IBI310 is anti CTLA-4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: IBI310 is anti CTLA-4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: IBI310 is anti CTLA-4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: IBI310 is anti CTLA-4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: IBI310 is anti CTLA-4 antibody
Study: NCT03585855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MSC transplantation
Description: MSC transplantation: patients with ABMR treated with MSC transplantation
Study: NCT00792298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: oral tablet taken before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: oral tablet taken before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: oral tablet taken before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: oral tablet taken before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: oral tablet taken before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: oral tablet taken before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: oral tablet taken before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: oral tablet taken before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to Suvorexant
Description: Dose-matched placebo to suvorexant taken before bedtime (oral tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to Suvorexant
Description: Dose-matched placebo to suvorexant taken before bedtime (oral tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to Suvorexant
Description: Dose-matched placebo to suvorexant taken before bedtime (oral tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to Suvorexant
Description: Dose-matched placebo to suvorexant taken before bedtime (oral tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to Suvorexant
Description: Dose-matched placebo to suvorexant taken before bedtime (oral tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to Suvorexant
Description: Dose-matched placebo to suvorexant taken before bedtime (oral tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to Suvorexant
Description: Dose-matched placebo to suvorexant taken before bedtime (oral tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to Suvorexant
Description: Dose-matched placebo to suvorexant taken before bedtime (oral tablet)
Study: NCT06091644

Intervention type: DEVICE
Group type: OTHER
Intervention: AirAngel® 3D printed videolaryngoscope
Description: This is a mannequin study that aims to compare a videolaryngoscope produced with 3D printing with a Storz videolaryngoscope and a Macintosh direct laryngoscope in the hands of inexperienced users in terms of ease of use, glottic imaging and intubation success.
Study: NCT01590342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Diclofenac 75 mg, two doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, two doses
Study: NCT04093648

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TEGAR T cells
Description: Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:DL1: 1x10\^7/m2 DL2: 3x10\^7/m2 DL3: 1x10\^8/m2 DL4: 3x10\^8/m2 DL5: 1x10\^9/m2 If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10\^6/m2 dose.~The first patient on each dose level has to be 28 days post-CAR T cell infusion before the second patient can be enrolled. The doses are calculated according to the actual number of GPC3-CAR transduced T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
Study: NCT01766947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensimed Triggerfish
Description: Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
Study: NCT01551693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090
Study: NCT04280432

Intervention type: PROCEDURE
Intervention: CESAREAN
Description: Women hospitalized for cesarean section
Study: NCT03093155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone
Description: Ixabepilone will be administered at 20 mg/m2 intravenously days 1, 8, 15 of a 28-day cycle over one hour.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Ixabepilone will be administered at 20 mg/m2 intravenously days 1, 8, 15 of a 28-day cycle over one hour.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at 10 mg/kg intravenously days 1, 15 of a 28-day cycle over one hour. Bevacizumab will be infused after ixabepilone. The first dose of bevacizumab will be administered intravenously over 90 minutes; the second dose may be administered over 60 minutes if no prior reaction to previous infusion; subsequent doses may be administered over 30 minutes if no prior reaction to previous infusion.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response.
Study: NCT02310620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: regular playing with the logic games developed in the framework of the M3W (Mental Wellness Toolset) project (https://m3w-project.eu/)
Study: NCT02504554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Vancomycin
Description: an antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Vancomycin
Description: an antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MoviPrep
Description: a bowel cleanse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MoviPrep
Description: a bowel cleanse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilosec
Description: a stomach acid suppressan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilosec
Description: a stomach acid suppressan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human fecal material; processed, frozen administered orally
Description: human fecal material; processed, frozen, administered orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human fecal material; processed, frozen; administered orally and rectally
Description: human fecal material; processed, frozen; administered orally and rectally
Study: NCT01567644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)
Description: Energy Density - 0.09 mJ/mm2
Study: NCT04456829

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol drink
Description: Subjects will consume a bottle of resveratrol drink for two months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Subjects will consume a bottle of placebo drink for two months.
Study: NCT02159144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold stress
Study: NCT04531475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X842
Description: X842 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X842
Description: X842 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X842 Placebo
Description: X842 placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Placebo
Description: Lansoprazole placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Placebo
Description: Lansoprazole placebo-matching capsules
Study: NCT03545971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: PD-1 monoclonal antibody
Study: NCT02052713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg
Description: Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fasted condition.
Study: NCT04134494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablative Fractional 2940 nm Laser
Description: * Treatment visit 1, month 0: On the first pass, the depth of the laser will be from 300 to 500 microns, or the thickness of 3 to 5 sheets of paper; the depth will be based on the biopsy that was used to diagnosis the lichen sclerosus. On the second pass, the depth will be 50 microns deeper than the first pass and the hand piece rotated 45˚.~* Treatment visit 2, month 1: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚.~* Treatment visit 3, month 2: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚.
Study: NCT02221544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency repetitive Transcranial Magnetic Stimulation
Description: Participants will receive treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions). In each session patient will receive repetitive Transcranial Magnetic Stimulation using a stimulation frequency of 10 Hz for half an hour.~The treatment is done by attaching an electromagnetic coil to the scalp using a special hat. Each patient has a personal hat which serves him throughout the entire process. The treatment is performed without anesthesia and patient fully conscious. During the treatment he sits comfortably on a chair, meanwhile the magnetic field passes through the skull into the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency repetitive Transcranial Magnetic Stimulation
Description: Participants will receive treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions). In each session patient will receive repetitive Transcranial Magnetic Stimulation using a stimulation frequency of 10 Hz for half an hour.~The treatment is done by attaching an electromagnetic coil to the scalp using a special hat. Each patient has a personal hat which serves him throughout the entire process. The treatment is performed without anesthesia and patient fully conscious. During the treatment he sits comfortably on a chair, meanwhile the magnetic field passes through the skull into the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS maintenance
Description: Same treatment as in rTMS treatment intervention, but only once a week for a month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS maintenance
Description: Same treatment as in rTMS treatment intervention, but only once a week for a month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Participants will receive sham treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions total) for half an hour each session. The treatment is done by attaching an electromagnetic coil to the scalp but without turning on the magnetic field.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Participants will receive sham treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions total) for half an hour each session. The treatment is done by attaching an electromagnetic coil to the scalp but without turning on the magnetic field.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham maintenance
Description: The same as Sham stimuli intervention, but once a week for a month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham maintenance
Description: The same as Sham stimuli intervention, but once a week for a month
Study: NCT00035451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azimilide Dihydrochloride
Description: 125 mg azimilide tablets, twice a day for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets, twice daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotalol
Description: 160 mg sot twice daily for 6 months
Study: NCT01618292

Intervention type: PROCEDURE
Intervention: Robotic sacral colpopexy
Description: Patients who underwent robotic assisted sacral colpopexy for the treatment of pelvic organ prolapse
Study: NCT01140009

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fluviral 2010/11 Tri-valent Seasonal Influenza vaccine
Description: Vaccination of .05mL of Fluviral vaccine will be injected once at either visit 1 or 2 depending upon randomization in the deltoid muscle of the non-dominant arm
Study: NCT02052713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
Description: Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
Description: Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fasted condition.
Study: NCT04382989

Intervention type: DEVICE
Intervention: Analysis of human milk composition by mid-infrared spectrophotometry
Description: Analysis of human milk macronutrient content was performed by mid-infrared spectrophotometry using a Miris Human Milk Analyser.~An immune-enzymatic ELISA assays were used to estimate lysozyme and lactoferrin concentrations in human milk.

Intervention type: DEVICE
Intervention: Analysis of human milk composition by mid-infrared spectrophotometry
Description: Analysis of human milk macronutrient content was performed by mid-infrared spectrophotometry using a Miris Human Milk Analyser.~An immune-enzymatic ELISA assays were used to estimate lysozyme and lactoferrin concentrations in human milk.